Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MSH3 mutS homolog 3 (E. coli)

Written2006-07Enric Domingo, Simo Schwartz Jr
Oncologia Molecular i Envelliment, Centre d'Investigacions en Bioqumica i Biologia Molecular (CIBBIM) Hospital Universitari Vall d'Hebron Passeig Vall d'Hebron 119-129 Barcelona 08035, Catalonia, Spain

(Note : for Links provided by Atlas : click)

Identity

Other aliasDUP
hMSH3
MRP1
LocusID (NCBI) 4437
Atlas_Id 341
Location 5q14.1  [Link to chromosome band 5q14]
Location_base_pair Starts at and ends at bp from pter
Local_order Between the DHFR and RASGRF2 genes.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
MSH3 (5q14.1) / MSH3 (5q14.1)

DNA/RNA

Description The MSH3 gene is composed of 24 exons spanning in a region of 222 Kb.
Transcription There are two major transcripts of 5 kb and 3,8 kb under the control of two different polyadenilation sites.

Protein

Description Amino acids: 1137. Molecular Weight: 127 KDa. MSH3 is a protein involved in the mismatch repair process after DNA replication.
Expression Expression of MSH3 together with the dihydrofolate reductase (DHFR) gene appear to be regulated by a bidirectional promoter composed of multiple GC boxes and two initiator elements. MSH3 is expressed in all human tissues at low levels but with variable intensities, with higher expression in testis and pancreas and lower in small intestine and colon.
Function MSH3 binds to MSH2 to form the MutSb heterodimer, which binds to insertion-deletion mismatches of two or more base pairs. Thereafter the MutS complex associates with the MutL complex and recruits the proteins needed for DNA excision and repair.
Homology MSH3 is homologue to the bacterial MutS gene and to the Msh3 gene in S. cerevisiae. Homology is higher in the C-terminal region.

Mutations

Somatic MSH3 has insertions/deletions in a A(8) repeat in tumours showing microsatellite instability (MSI). As MSH3 is a mismatch repair gene and is mutated in a microsatellite only in MSI tumours is considered to be a secondary mutator that enhances a more severe MSI.

Implicated in

Note
  
Entity MSI (MicroSatellite Instability).
Note Tumours in which the molecular feature that leads to cancer is the lost of the mismatch repair (MMR) system.
Disease This phenotype is present in 15% of colorectal cancer, gastric cancer and endometrial cancer, and with lower incidence in some other tissues.
Oncogenesis The average frequencies of the microsatellite mutation reported in sporadic MSI from colorectal, gastric and endometrial cancer are 38%, 39% and 25% respectively. In hereditary MSI (or HNPCC) is 51%.
  
  
Entity Hematological malignancies.
Oncogenesis It has been reported loss of expression of MSH3 at the mRNA level in some hematological malignancies including chronic myelogenous leukemia and acute myelogenous leukemia, acute lymphocytic leukemia and myelodysplastic syndrome.
  

Bibliography

Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability.
Duval A, Hamelin R
Cancer research. 2002 ; 62 (9) : 2447-2454.
PMID 11980631
 
Isolation and characterization of cDNA clones derived from the divergently transcribed gene in the region upstream from the human dihydrofolate reductase gene.
Fujii H, Shimada T
The Journal of biological chemistry. 1989 ; 264 (17) : 10057-10064.
PMID 2722860
 
Loss of expression of the human MSH3 gene in hematological malignancies.
Inokuchi K, Ikejima M, Watanabe A, Nakajima E, Orimo H, Nomura T, Shimada T
Biochemical and biophysical research communications. 1995 ; 214 (1) : 171-179.
PMID 7669036
 
DNA mismatch repair defects: role in colorectal carcinogenesis.
Jacob S, Praz F
Biochimie. 2002 ; 84 (1) : 27-47.
PMID 11900875
 
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.
Risinger JI, Umar A, Boyd J, Berchuck A, Kunkel TA, Barrett JC
Nature genetics. 1996 ; 14 (1) : 102-105.
PMID 8782829
 
Genomic organization and expression of the human MSH3 gene.
Watanabe A, Ikejima M, Suzuki N, Shimada T
Genomics. 1996 ; 31 (3) : 311-318.
PMID 8838312
 
HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions.
de Wind N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, van der Valk M, van't Wout K, te Riele H
Nature genetics. 1999 ; 23 (3) : 359-362.
PMID 10545954
 

Citation

This paper should be referenced as such :
Domingo, E ; Schwartz, S Jr. MSH3 (mutS homolog 3 (E
coli))
Atlas Genet Cytogenet Oncol Haematol. 2006;10(4):251-252.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/MSH3ID341ch5q11.html


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 4 ]
  Breast tumors : an overview
Colon: Colorectal adenocarcinoma
Breast: Ductal carcinoma
Gastric Tumors: an overview


External links

Nomenclature
Cards
AtlasMSH3ID341ch5q11.txt
Aliases
Genomic and cartography
Gene and transcription
RefSeq transcript (Entrez)
RefSeq genomic (Entrez)
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
BioGPS (Tissue expression)4437
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Protein Interaction databases
Ontologies - Pathways
Clinical trials, drugs, therapy
Miscellaneous
canSAR (ICR) (select the gene name)
Probes
Litterature
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 18 17:44:09 CEST 2018

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.